INVIVYD INC (IVVD)

US00534A1025 - Common Stock

4  +0.34 (+9.29%)

Premarket: 3.93 -0.07 (-1.75%)

News Image
an hour ago - Invivyd

Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights

Received emergency use authorization for PEMGARDA™, a monoclonal antibody (mAb) authorized in the U.S. for pre-exposure prophylaxis (PrEP) of COVID-19 in...

News Image
3 days ago - Chartmill

Top movers in Monday's session

Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

News Image
3 days ago - Chartmill

Top movers in Monday's session

Monday's session: top gainers and losers

News Image
3 days ago - Chartmill

The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

News Image
6 days ago - Chartmill

Which stocks are moving after the closing bell on Friday?

After hours stock analysis on 2024-03-22: top gainers and losers in today's session.

News Image
6 days ago - Invivyd

Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial

WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced interim exploratory COVID-19 clinical event data for VYD222, an investigational, monoclonal antibody (mAb) in development for the pre-exposure prophylaxis of COVID-19. The data announced today from the ongoing Phase 3 CANOPY clinical trial reflect and add further to the initial potential signal of clinical protection from symptomatic COVID-19 shared in December 2023, and may be useful in updating prior published work that analyzed the relationships between serum virus neutralizing antibody (sVNA) titers and protection in patients who had no prior exposure to vaccination or natural infection.1

News Image
6 days ago - Invivyd

Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

PEMGARDA (pemivibart) is authorized in the U.S. for PrEP of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise Emergency...

News Image
a month ago - Seeking Alpha

Invivyd stock falls 13% in wake of cash crunch disclosure (NASDAQ:IVVD)

Invivyd (IVVD) stock was down 13% in late morning trading Monday in the wake of news that the company had concerns about its ability to stay in business long term. Read more here.

News Image
2 months ago - Seeking Alpha

Invivyd files to sell 37.75M common shares for holders (NASDAQ:IVVD)

Invivyd files prospectus for resale of 37.75M common shares by selling stockholders; SEC filing linked.

News Image
2 months ago - Invivyd

Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

WALTHAM, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from...

News Image
2 months ago - InvestorPlace

3 Groundbreaking Biotech Stocks to Invest in Now

These are several biotech companies for investors seeking unique opportunities for great returns within the industry.

News Image
3 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

The biggest pre-market stock movers for Wednesday are ready to go as we break down all of the latest news moving shares today!

News Image
3 months ago - Seeking Alpha

Invivyd requests FDA authorization for COVID-19 treatment (NASDAQ:IVVD)

Invivyd (IVVD) has requested FDA Emergency Use Authorization for its treatment VYD222 for the prevention of COVID-19 in immunocompromised people. Read more here.

News Image
3 months ago - The Motley Fool

Invivyd Stock More Than Doubled Last Week. Is It Too Late to Buy?

The clinical-stage biotech delivered positive trial results for its new COVID-19 preventative antibody treatment.

News Image
3 months ago - Seeking Alpha

Invivyd stock slides 16% after rallying 120% in prior session (NASDAQ:IVVD)

Invivyd (IVVD) shares retreated 16% Tuesday after soaring 120% in the prior session on positive Phase 3 data for its COVID-19 drug VYD222. Read more here.

News Image
3 months ago - Invivyd

Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19

Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19...

News Image
5 months ago - Invivyd

Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Enrollment completed in CANOPY Phase 3 pivotal clinical trial investigating VYD222 for the prevention of symptomatic COVID-19Company expects to have...